Allergan PLC. (AGN) Rating Reiterated by Deutsche Bank AG

Deutsche Bank AG reiterated their buy rating on shares of Allergan PLC. (NYSE:AGN) in a report published on Tuesday. Deutsche Bank AG currently has a $262.00 price objective on the stock.

AGN has been the topic of several other reports. Cowen and Company set a $400.00 target price on Allergan PLC. and gave the company a buy rating in a report on Thursday, June 8th. Sanford C. Bernstein reiterated an outperform rating on shares of Allergan PLC. in a report on Thursday, May 25th. Mizuho reduced their target price on Allergan PLC. from $275.00 to $267.00 and set a buy rating on the stock in a report on Friday, June 9th. Royal Bank Of Canada reiterated a buy rating and issued a $285.00 target price on shares of Allergan PLC. in a report on Wednesday, September 6th. Finally, Cantor Fitzgerald initiated coverage on Allergan PLC. in a report on Friday, June 16th. They issued a neutral rating and a $231.00 target price on the stock. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and fifteen have issued a buy rating to the company. Allergan PLC. has a consensus rating of Buy and a consensus price target of $274.69.

Shares of Allergan PLC. (AGN) opened at 220.29 on Tuesday. The company has a 50 day moving average of $231.75 and a 200-day moving average of $236.59. Allergan PLC. has a 12 month low of $184.50 and a 12 month high of $256.80. The firm has a market capitalization of $73.64 billion, a P/E ratio of 6.71 and a beta of 1.18.

Allergan PLC. (NYSE:AGN) last announced its earnings results on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The business had revenue of $4.01 billion for the quarter, compared to analysts’ expectations of $3.95 billion. During the same period in the prior year, the business posted $3.35 earnings per share. The firm’s revenue was up 8.8% on a year-over-year basis. Analysts predict that Allergan PLC. will post $16.25 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Allergan PLC. (AGN) Rating Reiterated by Deutsche Bank AG” was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/09/16/allergan-plc-agn-rating-reiterated-by-deutsche-bank-ag.html.

The company also recently announced a quarterly dividend, which was paid on Friday, September 15th. Stockholders of record on Friday, August 18th were given a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.27%. The ex-dividend date of this dividend was Wednesday, August 16th. Allergan PLC.’s payout ratio is 9.95%.

Several large investors have recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Allergan PLC. by 2.2% during the second quarter. Vanguard Group Inc. now owns 22,835,689 shares of the company’s stock worth $5,551,128,000 after purchasing an additional 482,220 shares during the period. Northern Trust Corp raised its position in shares of Allergan PLC. by 8.8% during the second quarter. Northern Trust Corp now owns 4,492,944 shares of the company’s stock worth $1,092,189,000 after purchasing an additional 364,722 shares during the period. Veritas Asset Management LLP acquired a new position in shares of Allergan PLC. during the first quarter worth approximately $761,339,000. Edgewood Management LLC raised its position in shares of Allergan PLC. by 7.0% during the first quarter. Edgewood Management LLC now owns 2,704,211 shares of the company’s stock worth $646,090,000 after purchasing an additional 178,055 shares during the period. Finally, Epoch Investment Partners Inc. raised its position in shares of Allergan PLC. by 3.8% during the first quarter. Epoch Investment Partners Inc. now owns 2,013,415 shares of the company’s stock worth $481,045,000 after purchasing an additional 73,081 shares during the period. 82.06% of the stock is currently owned by institutional investors.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Analyst Recommendations for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply